OBIO Orchestra BioMed Holdings, ...

Nasdaq N/A


$ 3.82 $ 0.24 (6.74 %)    

Thursday, 23-Oct-2025 15:59:27 EDT
QQQ $ 611.70 $ 5.09 (0.84 %)
DIA $ 467.20 $ 1.51 (0.32 %)
SPY $ 672.21 $ 3.96 (0.59 %)
TLT $ 91.38 $ -0.63 (-0.68 %)
GLD $ 378.90 $ 1.51 (0.4 %)
$ 3.8
$ 3.56
$ 3.20 x 30
$ 3.95 x 500
$ 3.54 - $ 3.86
$ 2.20 - $ 6.50
238,012
na
205.03M
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 01-25-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-10-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 orchestra-biomed-to-present-data-summary-supporting-transformative-potential-of-avim-therapy-in-management-of-hypertensive-heart-disease-at-georgia-innovation-summit-in-tbilisi

Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progre...

 obio-highlights-long-term-durability-of-avim-therapy-in-major-clinical-publications-and-hrx-2025-presentation

Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025...

 orchestra-biomed-reports-long-term-reversible-blood-pressure-benefits-of-avim-therapy-results-support-durable-programmable-treatment-for-uncontrolled-hypertension

Results from long-term follow up of patients treated with atrioventricular interval modulation ("AVIM") therapy show bl...

 hc-wainwright--co-maintains-buy-on-orchestra-biomed-hldgs-lowers-price-target-to-10

HC Wainwright & Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price targe...

 btig-downgrades-orchestra-biomed-hldgs-to-neutral

BTIG analyst Marie Thibault downgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Buy to Neutral.

 orchestra-biomed-publishes-avim-therapy-clinical-data-in-jacc-advances

Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation ("AVIM") therapy ...

 chardan-capital-maintains-buy-on-orchestra-biomed-hldgs-maintains-20-price-target

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

 orchestra-biomed-hldgs-q2-eps-050-beats-051-estimate-sales-836000k-beat-695600k-estimate

Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate o...

 chardan-capital-maintains-buy-on-orchestra-biomed-hldgs-maintains-20-price-target

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

Core News & Articles

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company acce...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION